This site is intended for health professionals only!

Published on 20 February 2009

Share this story:
Twitter
LinkedIn

UCB to divest Equasym

teaser

UCB has agreed the sale of Equasym IR and Equasym XL (methylphenidate HCl) for the treatment of attention deficit hyperactivity disorder (ADHD) to Shire, a specialty biopharmaceutical company.

With the exception of the US, Canada and Barbados, world-wide product rights and relevant staff for Equasym IR/XL are being acquired by Shire. UCB will receive an up-front payment totalling €55 million and additional undisclosed milestone payments if Shire meets certain pre-defined sales targets. Equasym IR/XL sales in 2008 were approximately €17 million.

The transaction is expected to close in the second quarter 2009 and is subject to standard closing conditions. In the US, UCB will continue to market Metadate CD (methylphenidate HCl) extended release tablet for the treatment of ADHD. Further details of the transaction are not disclosed.

“ADHD is a behavioural disorder mainly treated by paediatric psychiatrists and paediatricians. With this agreement, UCB further underlines its SHAPE programme and focuses its CNS franchise on our core products bringing new innovative medicines to people living with severe neurological conditions,” said Troy Cox, President CNS Operations UCB.

To read more on this release, please click on the link below:

UCB



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn